Table 4.
Neuroimaging Markers by Study Arm
| PI-mono (n = 39) | OT (n = 39) | P Value | |
|---|---|---|---|
| WMH | |||
| WMH present, N (%) | 22 (56.4) | 25 (64.1) | .64 |
| Volume (mm3), median (IQR) | 76 (0–667) | 101 (0–347) | .91 |
| Atrophy measures | |||
| GCA score, median (IQR) | 1 (0–2) | 1 (1–1) | .60 |
| TLA score, median (IQR) | 1 (1–2) | 1 (1–1) | .77 |
| Bicaudate index, median (IQR) | 0.11 (0.10–0.13) | 0.10 (0.09–0.12) | .07 |
| Single Voxel MRS | |||
| NAA/Cho, median (IQR) | 4.2 (3.9–4.8) | 4.4 (4.0–4.7) | .37 |
| NAA/Cr, median (IQR) | 1.0 (0.9 −1.0) | 1.0 (0.9–1.0) | .53 |
| mI/Cr, median (IQR) | 0.6 (0.5–0.7) | 0.5 (0.5–0.6) | .56 |
Abbreviations: GCA, global cortical atrophy score; IQR, interquartile range; mI/Cr, Myo-inositol to creatine ratio; MRS, magnetic resonance spectroscopy; NAA/Cho, N-acetyl aspartate to choline ratio; NAA/Cr, N-acetyl aspartate to creatine ratio; OT, ongoing triple therapy; PI, protease inhibitor; TLA, Medial temporal lobe atrophy score; WMH, White matter hyperintensities.